Safety of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

Albert Agro, PhD;1 Jordan Dubow, MD;2 Bruce Dzyngel;1 Thierry Bilbault, PhD;1 Anthony Giovinazzo;1 Stuart Isaacson, MD3

1Cynapsus Therapeutics, Toronto, Ontario, Canada; 2formerly of Cynapsus Therapeutics, Toronto, Ontario, Canada; 3Parkinson’s Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, United States

BACKGROUND

• Up to 2/3rds of Parkinson’s disease (PD) patients suffer from OFF episodes including:
  • Wearing OFF
  • Morning akinesia
  • Delayed/no-ON and sudden OFF
  • OFF episodes in PD have a significant negative impact on quality of life of patients
  • APL-130277 is a soluble, sublingual film strip of apomorphine (Figure 1)

RESULTS (continued)

Figures 3 and 4 show the primary efficacy endpoint: % of patients turning fully ON as confirmed by the Investigator following an APL-130277 administration.

Safety of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson’s Disease

Patients could be dosed up to two times/day over 3 days
• Pre-treatment with trimethobenzamide (anti-emetic) was started 3 days prior to initiation of APL-130277 and was continued during its dosing

CONCLUSIONS

• APL-130277 was generally well tolerated
• Most common AEs were mild to moderate and known dopaminergic AEs
• Adaptation of dopaminergic AEs (i.e. nausea) appears to occur during dose titration
• Dyskinesia was not reported as a treatment-related adverse events

ACKNOWLEDGEMENTS

This study was supported by Cynapsus Therapeutics. Additionally, the Michael J. Fox Foundation provided a grant in support of the study. BD, TB, AG and AA are employees of Cynapsus Therapeutics and hold stock or stock options. JD is a former employee of Cynapsus Therapeutics. SI was an Investigator in the study and received compensation from Cynapsus for research activities. APL-130277 is currently an investigational product in some countries, including the United States.